神経変性疾患治療薬の世界市場-2024～2031年

神経変性疾患治療薬の世界市場は、2023年に115億米ドルに達し、2031年には243億2,000万米ドルに達すると予測され、予測期間2024年にはCAGR 9.8％で成長する見込みです。

神経変性疾患は、神経細胞が徐々に変性して死滅する進行性の疾患群であり、特に脳と脊髄に影響を及ぼします。これらの疾患には、アルツハイマー病、パーキンソン病、ハンチントン病などのよく知られた疾患が含まれ、個人の認知機能や運動機能に深刻な影響を与える可能性があります。

これらの疾患の罹患率の上昇に伴い、神経変性疾患治療薬に対するニーズが高まっています。例えば、アルツハイマー病協会によると、2024年には65歳以上のアメリカ人のうち690万人がアルツハイマー病に罹患していると推定されています。700万人近くのアメリカ人がアルツハイマー病とともに生きています。2050年には、この数は1,300万人近くにまで増加すると予測されています。

神経変性疾患の治療薬を製造している製薬企業は、世界中で事業を拡大するために戦略的パートナーシップや提携を結んでいます。2024年12月、Novartisはハンチントン病（HD）の経口治療薬となる可能性のあるPTC518を開発するため、PTC Therapeuticsと世界のライセンスおよびパートナーシップ契約を締結しました。PTC518ハンチントン病プログラムには関連分子も含まれます。この提携により、Novartisは神経変性疾患への取り組みを強化することになります。

市場力学：

促進要因と阻害要因

革新的ソリューションに対する承認の増加

神経変性疾患治療薬市場は、医薬品承認の増加、高齢化人口の増加、アルツハイマー病、パーキンソン病、筋萎縮性側索硬化症（ALS）といった疾患の有病率の上昇といった要因によって大きく牽引されています。FDAやEMAのような規制当局がより多くの治療を承認することで、患者やヘルスケアプロバイダーは、患者のニーズに合わせた幅広い選択肢を利用できるようになります。

2024年9月、Rocheは再発性多発性硬化症（RMS）および原発性進行性多発性硬化症（PPMS）の治療薬として、「OCREVUS ZUNOVO」（一般名：ocrelizumab & hyaluronidase-ocsq）の米国食品医薬品局（FDA）承認を取得しました。OCREVUS ZUNOVOは、これら両方の多発性硬化症に対して最初で唯一承認された医療従事者（HCP）による年2回の約10分間の皮下（SC）注射剤であり、MS患者により多くの治療選択肢を提供します。この動向は、治療の個別化を促進するだけでなく、製薬企業間の競争を促進し、これらの疾患の複雑性に対処する革新的な解決策をもたらします。

世界人口の高齢化は、神経変性疾患の有病率上昇に寄与する重要な要因です。長生きする人が増えるにつれて、これらの疾患の発生率は大幅に増加すると予想されます。例えば、米国でアルツハイマー病と診断される人の数は、2022年の約650万人から2050年には1,270万人に増加すると予測されています。このような診断の急増は、効果的な治療に対する需要を増幅させ、これらの衰弱性疾患をターゲットにした医薬品の承認率の上昇を促しています。

企業は、単に症状を緩和するのではなく、疾患の進行を遅らせたり止めたりすることを目的とした疾患修飾療法の開発に注力しています。例えば、AbbVieは2024年1月、重度の運動変動とハイパーキネジア（過度の運動）またはジスキネジア（不随意運動）を伴う進行性パーキンソン病の治療を適応症とするPRODUODOPA（foslevodopa/foscarbidopa）を欧州連合（EU）で発売しました。このような革新的な治療アプローチへのシフトは、神経変性疾患治療薬市場の予想成長率に反映されています。

副作用と安全性への懸念

アルツハイマー病やパーキンソン病などの神経変性疾患に対する現在の治療には重大な副作用が存在するため、神経変性疾患治療薬市場の成長には大きな障壁となっています。吐き気、疲労、認知障害を含む一般的な副作用は、患者のQOLを著しく低下させ、処方された治療法のアドヒアランス不良につながります。

このような副作用のために患者が薬物療法を中止すると、病気の進行が悪化するだけでなく、同じような副作用プロファイルを持つ可能性のある新しい薬物療法を試すことに対する一般的な消極性も助長されます。このような消極的な姿勢は、革新的な治療法に積極的に取り組もうとする患者層を減少させ、競合情勢の中で新薬が支持を得る可能性を制限することで、市場の成長を阻害する可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 革新的なソリューションに対する承認の増加
  • 抑制要因
    • 副作用と安全性の懸念
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 規制分析
• SWOT分析
• アンメットニーズ

第6章 疾患タイプ別

• パーキンソン病
• 筋萎縮性側索硬化症
• アルツハイマー病
• ハンチントン病
• その他

第7章 薬剤クラス別

• ドーパミン作動薬
• 脱炭酸酵素阻害剤
• コリンエステラーゼ阻害剤
• 免疫調節薬
• その他

第8章 投与経路別

• 経口
• 注射
• 経皮

第9章 エンドユーザー別

• 病院
• 専門クリニック
• その他

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第12章 企業プロファイル

• AbbVie Inc.
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• Amneal Pharmaceuticals LLC.
• Eisai Co., Ltd.
• F. Hoffmann-La Roche Ltd
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Otsuka Pharmaceutical Co., Ltd.
• Orion Corporation

第13章 付録

The global neurodegenerative disease therapeutics market reached US$ 11.50 billion in 2023 and is expected to reach US$ 24.32 billion by 2031, growing at a CAGR of 9.8% during the forecast period 2024-2031.

Neurodegenerative diseases are a group of progressive conditions that lead to the gradual degeneration and death of nerve cells, particularly affecting the brain and spinal cord. These disorders, which include well-known conditions such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, can severely impact an individual's cognitive and motor functions.

There is a growing need for neurodegenerative disease therapeutics with the rising incidence of these diseases. For instance, according to the Alzheimer's Association, An estimated 6.9 million Americans age 65 and older are existing with Alzheimer's in 2024. Nearly 7 million Americans are living with Alzheimer's. By 2050, this number is projected to rise to nearly 13 million.

The pharmaceutical companies manufacturing therapeutic drugs for neurodegenerative diseases are forming strategic partnerships and collaborations to expand their businesses around the globe. In December 2024, Novartis entered a worldwide licensing and partnership agreement with PTC Therapeutics to develop PTC518, a potential oral therapy for Huntington's disease (HD). The PTC518 Huntington's disease program also encompasses related molecules. The partnership is set to enhance Novartis' focus on neurodegenerative conditions.

Market Dynamics: Drivers & Restraints

Rising Approvals for Innovative Solutions

The neurodegenerative disease therapeutics market is driven significantly by a combination of increasing drug approvals, a growing aging population, and the rising prevalence of conditions such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). As regulatory agencies like the FDA and EMA approve more treatments, patients and healthcare providers gain access to a broader array of options tailored to meet divere patient needs.

In September 2024, Roche received the United States Food and Drug Administration approval for OCREVUS ZUNOVO (ocrelizumab & hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). OCREVUS ZUNOVO is the first and only twice-a-year, healthcare professional (HCP)-to administer approximately 10-minute subcutaneous (SC) injections approved for both these forms of multiple sclerosis, giving people living with MS more treatment options. This trend not only enhances treatment personalization but also fosters competition among pharmaceutical companies, leading to innovative solutions that address the complexities of these diseases.

The aging global population is a critical factor contributing to the rising prevalence of neurodegenerative diseases. With more individuals living longer, the incidence of these conditions is expected to increase substantially. For example, it is projected that the number of people diagnosed with Alzheimer's disease in the U.S. will rise from approximately 6.5 million in 2022 to 12.7 million by 2050. This surge in diagnoses amplifies the demand for effective treatments, prompting higher approval rates for drugs targeting these debilitating conditions.

Companies are focusing on developing disease-modifying therapies that aim to slow or halt disease progression rather than merely alleviating symptoms. For instance, in January 2024, AbbVie launched PRODUODOPA (foslevodopa/foscarbidopa) in the European Union for the treatment of advanced Parkinson's disease with severe motor fluctuations and hyperkinesia (excessive movement) or dyskinesia (involuntary movement). This shift towards innovative treatment approaches is reflected in the anticipated growth of the neurodegenerative disease therapeutics market.

Side effects and safety concerns

The presence of significant side effects in current treatments for neurodegenerative diseases, such as Alzheimer's and Parkinson's, presents a substantial barrier to the growth of the neurodegenerative disease therapeutics market. Common adverse effects, including nausea, fatigue, and cognitive disturbances, can severely diminish patients' quality of life, leading to poor adherence to prescribed therapies.

When patients discontinue their medications due to these side effects, it not only worsens the progression of the disease but also fosters a general reluctance to try newer medications that may share similar side effect profiles. This reluctance can hinder market growth by reducing the patient population willing to engage with innovative therapies, thus limiting the potential for new drugs to gain traction in a competitive landscape.

Segment Analysis

The global neurodegenerative disease therapeutics market is segmented based on disease type, drug class, route of administration, end-user, and region.

Drug class segment is expected to dominate the global neurodegenerative disease therapeutics market share

The drug class segment is expected to hold a dominant position in the neurodegenerative disease therapeutics market due to the diverse range of effective treatments available for various conditions, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. This segment encompasses several key categories, such as immunomodulators, dopamine agonists, cholinesterase inhibitors, and N-methyl-D-aspartate (NMDA) receptor antagonists, each playing a crucial role in managing symptoms and potentially modifying disease progression.

Dopamine agonists are also gaining traction, especially for Parkinson's disease management. Several companies are conducting rigorous research to innovate new therapeutics to treat neurodegenerative diseases effectively. For instance, in July 2023, Calibr, the drug discovery division of Scripps Research that translates innovative medicines from "bench to bedside," initiated a healthy volunteer first-in-human phase 1 clinical trial of PDM608 for the treatment of multiple neurodegenerative diseases.

Geographical Analysis

North America is expected to hold a significant position in the global neurodegenerative disease therapeutics market share

North America holds a dominant position in the global neurodegenerative disease therapeutics market and is expected to hold the major portion of the market during the forecast period. The region's market growth is attributed to the increasing incidence of neurodegenerative diseases, increasing research and development of innovative treatment options, the presence of a large number of multinational pharmaceutical companies in the region and the presence of strong regulatory support and increasing funding for neurodegenerative disease research.

Government funding plays a crucial role in driving the neurodegenerative disease therapeutics market in North America by supporting research, development, and innovation in this critical healthcare sector. With the rising funding, the research and development of innovative therapies are being raised which is expected to expand the region's market growth. For instance, following a $100 million increase signed into law in March 2024, and added to current NIH spending, annual federal funding for Alzheimer's research will be as much as $3.8 billion. Additionally, in fiscal year 2022, the NINDS funded approximately $125 million out of a total of $259 million in NIH-supported PD research.

Additionally, the increasing number of drug approvals is significantly driving the neurodegenerative disease therapeutics market in North America. With the increasing number of approvals in the region, there are rising treatment options for individuals who are in need. Companies are increasingly developing the neurodegenerative disease drugs to meet the growing demand. For instance, in August 2024, Amneal Pharmaceuticals, Inc. received the U.S. Food and Drug Administration (FDA) approved CREXONT (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson's disease (PD). CREXONT is a novel, oral formulation of carbidopa/levodopa (CD/LD) that combines both immediate-release (IR) granules and extended-release (ER) pellets.

In May 2024, Teva Pharmaceuticals received the U.S. Food and Drug Administration (FDA) approval for AUSTEDO XR as a one-pill, once-daily treatment option, now with four new tablet strengths (30, 36, 42, 48 mg) indicated in adults for TD and HD chorea.

Thus, the above factors are expected to expand North America's market share in the neurodegenerative disease therapeutics market.

Asia Pacific is growing at the fastest pace in the global neurodegenerative disease therapeutics market

The Asia-Pacific region is at the fastest growth in the global neurodegenerative disease therapeutics market, driven by several factors. One of the key factors for this growth is the rising prevalence of neurodegenerative diseases, such as Alzheimer's and Parkinson's due to which there is a heightened healthcare demand in countries like China and India. For instance, according to the report by the National Institute of Health in 2024, In 2021, China recorded the highest age-standardized incidence and prevalence of PD among the G20 countries, at 24.3 per 100,000 and 245.7 per 100,000, respectively. This prevalence is expected to rise and the demand for drugs and treatment is expected to increase in the region which is collectively increasing the region's market share.

The region's robust pharmaceutical industry significantly contributes to this growth, featuring a strong presence of both multinational and local companies that are actively engaged in research and development. This commitment enhances the availability of innovative therapies tailored to meet the needs of patients. For instance, in September 2024, Otsuka Pharmaceutical Co., Ltd. (Otsuka) obtained regulatory approval in Japan on an additional treatment indication for Rexulti (generic name: brexpiprazole), described as the treatment of "an excessive motor activity or physically/verbally aggressive behavior due to rapid changes in mood, irritability, and outbursts associated with dementia due to Alzheimer's disease. Thus, the above factors are expected to contribute to the fastest growth of the region's market.

Competitive Landscape

The major global players in the neurodegenerative disease therapeutics market include AbbVie Inc., Amneal Pharmaceuticals LLC., Eisai Co., Ltd., F. Hoffmann-La Roche Ltd, Merck KGaA, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co., Ltd. and Orion Corporation among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Neurodegenerative Disease Therapeutics market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Disease Type
• 3.2. Snippet by Drug Class
• 3.3. Snippet by Route of Administration
• 3.4. Snippet by End-User
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising Approvals for Innovative Solutions
  • 4.1.2. Restraints
    • 4.1.2.1. Side effects and safety concerns
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Disease Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 6.1.2. Market Attractiveness Index, By Disease Type
• 6.2. Parkinson's Disease*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Amyotrophic Lateral Sclerosis
• 6.4. Alzheimer's Disease
• 6.5. Huntington Disease
• 6.6. Others

7. By Drug Class

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 7.1.2. Market Attractiveness Index, By Drug Class
• 7.2. Dopamine Agonists*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Decarboxylase Inhibitors
• 7.4. Cholinesterase Inhibitors
• 7.5. Immunomodulators
• 7.6. Others

8. By Route of Administration

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 8.1.2. Market Attractiveness Index, By Route of Administration
• 8.2. Oral*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Injection
• 8.4. Transdermal

9. By End-User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.1.2. Market Attractiveness Index, By End-User
• 9.2. Hospitals*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Specialty Clinics
• 9.4. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.7.1. U.S.
    • 10.2.7.2. Canada
    • 10.2.7.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.7.1. Germany
    • 10.3.7.2. U.K.
    • 10.3.7.3. France
    • 10.3.7.4. Spain
    • 10.3.7.5. Italy
    • 10.3.7.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.7.1. Brazil
    • 10.4.7.2. Argentina
    • 10.4.7.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7.1. China
    • 10.5.7.2. India
    • 10.5.7.3. Japan
    • 10.5.7.4. South Korea
    • 10.5.7.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. AbbVie Inc.*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Amneal Pharmaceuticals LLC.
• 12.3. Eisai Co., Ltd.
• 12.4. F. Hoffmann-La Roche Ltd
• 12.5. Merck KGaA
• 12.6. Novartis AG
• 12.7. Pfizer Inc.
• 12.8. Teva Pharmaceutical Industries Ltd.
• 12.9. Otsuka Pharmaceutical Co., Ltd.
• 12.10. Orion Corporation

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us